Weekly gemcitabine and trastuzumab in the treatment of Patients with her2-overexpressing metastatic breast cancer

Clinical Breast Cancer

Volumn 9, Issue 3, 2009, Pages 178-183

  Yardley, Denise A ^a   Burris, Howard A ^a   Hanson, Sarah ^a   Greco, F Anthony ^a   Spigel, David R ^a   Barton, John ^a   Hainsworth, John D ^a  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

Filgrastim; Granulocyte colony stimulating factor; Myelosuppression; Neutropenia

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FULVESTRANT; GEMCITABINE; NAVELBINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAXANE DERIVATIVE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; HER2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADULT; AGED; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; BREAST METASTASIS; CANCER GROWTH; CANCER SURVIVAL; CLINICAL EVALUATION; CONGESTIVE HEART FAILURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; GENE OVEREXPRESSION; HEART EJECTION FRACTION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; NAUSEA; NEUTROPENIA; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; BIOSYNTHESIS; BREAST TUMOR; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 70350757862     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2009.n.029     Document Type: Article

References (26)

1. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
2. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.
3. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
4. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-20.
5. + overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. J Clin Oncol 2004;22:1071-7.
6. Burris H, Yardley D, Jones S, et al. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. J Clin Oncol 2004;22:1621-9.
7. Burstein HJ, Kuter I, Campos SM, et al. Clinical activity of trastuzumab and vinorelbine in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2001;19:2722-30.
8. Burstein HJ, Harris LN, Marcom K, et al. Trastuzumab and vinorelbine as firstline therapy for HER2-overexpressing metastatic breast cancer: Multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003;21:2889-95.
9. von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A German Breast Group 26/Breast International Group 3-05 study. J Clin Oncol 2009;27:1999-2006.
10. Gelmon KA, Mackey J, Verma S, et al. Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin Breast Cancer 2004;5:52-8.
11. Carmichael J, Possinger K, Phillip P, et al. Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 1995;13:2731-6.
12. Modi S, Currie VE, Seidman AD, et al. A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane. Clin Breast Cancer 2005;6:55-60.
13. O'Shaughnessy JA, Vukelja S, Marsland T, et al. Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. Clin Breast Cancer 2004;5:142-7.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
15. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 Study Group. J Clin Oncol 2005;23:4265-74.
16. Perez EA, Suman VJ, Rowland KM, et al. Tw o concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG Study 983252. Clin Breast Cancer 2005;6:425-32.
17. Brodowicz T, Kostler WJ, Moslinger R, et al. Single-agent gemcitabine as secondor third-line treatment in metastatic breast cancer. Breast 2000;9:338-42.
18. Spielmann M, Llombart-Cussac A, Kalla S, et al. Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology 2001;60:303-7.
19. Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2006;24:2786-92.
20. Peacock NW, Infante JR, Yardley DA, et al. Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer. J Clin Oncol 2008;26:49s (Abstract 1032).
21. Kash J, Barlow WE, Albain KS, et al. Phase II Southwest Oncology Group study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer. J Clin Oncol 2008;26:49s (Abstract 1033).
22. Beeram M, Burris HA, Modi S, et al. A phase I study of trastuzumab-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate in patients with advanced HER2+ breast cancer. J Clin Oncol 2008;26(suppl) :48s (Abstract 1028).
23. Holden SN, Beeram M, Krop IE, et al. A phase I study of weekly dosing of trastuzumab-DM1 (T-DM1) in patients with advanced HER2+ breast cancer. J Clin Oncol 2008;26(suppl) :48s (Abstract 1029).
24. Gelmon KA, Fumoleau P, Verona S, et al. Results of a phase II trial of trastuzumab and pertuzumab in patients with HER2-positive metastatic breast cancer who had progressed during trastuzumab therapy. J Clin Oncol 2008;26(suppl) :47s (Abstract 1026).
25. Modi S, Sugarman S, Stopeck A, et al. Phase II trial of the Hsp90 inhibitor tanespimycin + trastuzumab in patients with HER2-positive metastatic breast cancer. J Clin Oncol 2008;26(suppl) :47s (Abstract 1027).
26. Gianni L, Eiermann W, Pusztai L, et al. Biomarkers as potential predictors of pathologic complete response (pCR) in the NOAH trial of neoadjuvant trastuzumab in patients (pts) with HER2-positive locally advanced breast cancer (LABC). J Clin Oncol 2008;26(suppl) :8s (Abstract 504).